首頁 > 市場調查報告書 > 醫療設備

藥物遞輸設備

市場調查報告書

商品編碼

1319138

全球自動注射器市場 - 2023-2030 年

Global Autoinjectors Market - 2023-2030

出版日期: 2023年07月31日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概述

全球自動注射器市場規模在2022 年達到87 億美元，預計到2030 年將達到297 億美元，2023-2030 年的年複合成長率為17.2%。推動全球自動注射器市場成長的因素包括：技術進步、人口老齡化加劇、癌症和糖尿病等慢性病發病率上升、患者醫療保健支出增加以及研發活動日益增多。

自動注射器是一類重要的醫療器械，可通過皮下或肌肉注射途徑給藥。它們可以方便地自行給藥，而且劑量準確。它可以立即治療過敏性休克、偏頭痛等急症和糖尿病、多發性硬化症、類風濕性關節炎等其他慢性疾病。

市場動態

多發性硬化症發病率的增加促進了市場成長

多發性硬化症發病率的增加在促進市場成長方面發揮了重要作用。多發性硬化症（MS）是一種潛在的大腦和脊髓（中樞神經系統）致殘性疾病。多發性硬化症患者的免疫系統會攻擊覆蓋神經纖維的保護鞘（髓鞘），從而導致大腦與身體其他部位之間的通訊問題。

多發性硬化症患者人數的增加將增加自動注射器的使用量。例如，據多發性硬化症探索論壇稱，全球約有250 萬人患有多發性硬化症。據估計，美國每週新增200 例診斷病例。因此，多發性硬化症病例的增加推動了市場的成長。

老年人口的增加放大了市場成長

老年人口發病率的增加正在擴大市場的成長。年齡因素將影響市場。由於老年人的增加，他們無法長期住院治療。老年人更容易患哮喘、糖尿病等疾病。

為了規避風險，老年人群會選擇便捷的方法。因此，老年人口的增加將推動市場的發展。例如，根據美國國立衛生研究院（NIH）的報告，老年患者與哮喘相關的死亡率最高，每百萬人中有51.3 人。因此，老年人口的增加將擴大市場成長。

與設備相關的併發症將抑制市場成長

與使用設備相關的併發症會降低市場成長。使用自動注射器會產生許多副作用和併發症。例如，根據歐洲心臟病學會的研究，與自動注射器相關的副作用包括心跳加快/加速、緊張、出汗、噁心、嘔吐、呼吸困難、頭痛、頭暈、焦慮、顫抖或皮膚蒼白。因此，該設備併發症的增加會對市場產生負面影響。

COVID-19 影響分析

COVID-19 的流行加快了自我注射的趨勢，使患者能夠更積極地控制治療。這一方向促進了自動注射器市場的更新技術，以加強注射速度調節、注射部位疼痛和治療焦慮。

此外，在COVID-19 大流行期間，主要企業推出的新產品也推動了市場的發展。例如，2020 年4 月，梯瓦製藥美國公司宣布，AJOVY（fremanezumab-vfrm）注射劑的自動注射器裝置已在美國上市。 AJOVY適用於成人偏頭痛的預防性治療，是唯一可選擇每季度（675 毫克）和每月（225 毫克）皮下注射給藥的抗降鈣素基因相關肽（CGRP）預防性偏頭痛治療藥物。

此外，諾華公司於2021 年9 月報告了一項國際IIIb 期研究的數據，該研究顯示，用2 毫升自動注射器（UnoReady 筆）注射300 毫克Cosentyx（secukinumab）治療輕度至重度斑塊狀銀屑病成人患者，療效顯著，用藥正確1。這些數據已在歐洲皮膚病與性病學會30 週年大會上公佈。

此外，儘管大流行病帶來了嚴峻的現實，但更廣泛的給藥市場歷來表現出持續、健康的成長。隨著全球開始從COVID-19 的長期影響中恢復過來，並接近一個更加穩定和正常的時期，市場有望蓬勃發展。

俄烏戰爭影響分析

據估計，俄烏衝突對自動注射器市場的影響不大，因為該地區的主要市場參與者較少。不過，在預測期內，原料進出口的影響預計對自動注射器市場的成長影響不大。

Market Overview

Global Autoinjectors Market reached US$ 8.7 billion in 2022 and is expected to reach US$ 29.7 billion by 2030 growing with a CAGR of 17.2% during the forecast period 2023-2030. The global autoinjectors market growth is driven by technological advancements, an increasingly aging population, a rising prevalence of chronic diseases such as cancer and diabetes, rising patient healthcare expenditure and growing research and development activities.

These are important classes of medical devices that can deliver drugs through the subcutaneous or intramuscular route. They can be easily self-administered, and accurate doses can be given. It is an immediate treatment for emergency conditions such as anaphylaxis, migraine, and other chronic diseases such as diabetes, multiple sclerosis, rheumatoid arthritis, and others.

Market Dynamics

An increase in the Incidence of Multiple Sclerosis is Boosting the Market Growth

An increase in the incidence of multiple sclerosis cases is playing a major role in boosting market growth. Multiple sclerosis (MS) is a potentially disabling disease of the brain and spinal cord (central nervous system). In MS, the immune system attacks the protective sheath (myelin) that covers nerve fibers and causes communication problems between your brain and the rest of your body.

An increase in the number of MS patients will increase the usage of autoinjectors. For instance, according to the MS Discovery Forum, an estimated 2.5 million people live with multiple sclerosis worldwide. An estimated 200 new cases are diagnosed each week in the United States. Thus, an increase in the number of MS cases is driving the market growth.

An Increase in the Geriatric Population is Magnifying the Market Growth

The increase in the incidence of the geriatric population is expanding the growth of the market. The age factor will influence the market. As there is an increase in aged people, they cannot go for hospitalization for a long period. Aged people are more prone to diseases such as asthma, diabetes, and many others.

In order to avoid the risks, aged groups will prefer convenient methods. Thus, an increase in the number of aged population will drive the market. For instance, according to NIH, elderly patients have the highest reported asthma-related mortality at 51.3 per million persons. Thus increase in the number of older population will expand the market growth.

Complications Associated with the Devices will Decline the Market Growth

The complications associated with the use of the devices can decline the growth of the market. There are a number of side effects and complications associated with the use of auto-injectors. For instance, according to the European Society of Cardiology, the side effects associated with auto-injector are fast/pounding heartbeat, nervousness, sweating, nausea, vomiting, trouble breathing, headache, dizziness, anxiety, shakiness, or pale skin may occur. Thus, an increase in the complications of the devices can affect the market negatively.

COVID-19 Impact Analysis

The COVID-19 epidemic has quickened the trend of self-injection, allowing patients to become more active and in control of their treatment. The direction has promoted newer technologies in the autoinjectors market for enhanced injection speed regulation, injection site pain, and treat anxiety.

In addition, the new products launched by key players are driving the market during the COVID-19 pandemic. For instance, in April 2020, Teva Pharmaceuticals USA, Inc. announced that the autoinjector device for AJOVY (fremanezumab-vfrm) injection is available in the United States. AJOVY is implied for the preventive treatment of migraine in adults and is the only anti-CGRP (calcitonin gene-related peptide) preventive migraine treatment with quarterly (675 mg) and monthly (225 mg) subcutaneous dosing options.

Also, in September 2021, Novartis reported data from an international Phase IIIb study, which delivered treatment with Cosentyx (secukinumab) 300 mg in a 2 mL autoinjector (UnoReady pen) resulted in high effectiveness and proper administration in adults with mild to severe plaque psoriasis1. These data were presented at the European Academy of Dermatology and Venereology's 30th Anniversary Congress.

Moreover, the broader drug delivery market has historically shown consistent, healthy growth, despite the grim realities of the pandemic. As the world begins to recover from the long-lasting effects of COVID-19 and approaches a period of greater stability and normality, markets are expected to flourish.

Russia-Ukraine War Impact Analysis

The Russia-Ukraine conflict is estimated to have a moderate impact on the Autoinjectors Market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the Autoinjectors Market growth over the forecast period.

Segment Analysis

The autoinjectors market is segmented based on type, application, and end user.

The Type-2 Diabetes Mellitus Segment Accounts for Approximately 34.7% of the Autoinjectors Market Share

Due to the rise in the number of type-2 diabetic patients diseases, the segment holds the highest market share. For instance, according to Healthline, about 1.4 million new cases of diabetes are diagnosed in the United States every year. More than one in every ten adults who are 20 years or older has diabetes. For seniors (65 years and older), that figure rises to more than one in four.

Geographical Analysis

Europe accounted for Approximately 28.4% of the Market Share Owing to Technological Advancements

The rise in collaborations, clinical trials, and innovation of new devices is holding this region in this position. A number of clinical trials and approvals have been taking place in this region in order to make patients available for a number of treatments.

For instance, Aptar Pharma teams up with BD to develop a novel auto-injector. Aptar Pharma has signed an exclusive development and license agreement with BD Becton, Dickinson, and Company (BD). Thus, the increase in company collaborations, technological advancements, and new innovations is raising the growth of the market.

Competitive Landscape

The major global players in the autoinjectors market include: AbbVie, Amgen, Biogen Idec, AstraZeneca, Mylan, Pfizer, Teva Pharmaceuticals, Merck & Co, Johnson & Johnson, and Becton Dickinson and Company among others.

Why Purchase the Report?

To visualize the auto-injector segmentation based on type, application, end-user, and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of Autoinjectors Market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The Autoinjectors Market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet By Type
3.2. Snippet By Application
3.3. Snippet By End User
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Increased number of people with allergies
  - 4.1.1.2. Increase in the number of chronic diseases
- 4.1.2. Restraints
  - 4.1.2.1. Complications associated with the devices
- 4.1.3. Opportunity
  - 4.1.3.1. Increased number of clinical trials and new launches of devices
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. By Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 7.1.2. Market Attractiveness Index, By Type
7.2. Disposable Autoinjectors
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Reusable Autoinjectors

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Rheumatoid Arthritis
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Psoriatic Arthritis
8.4. Type II Diabetes Mellitus
8.5. Others

9. By End User

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 9.1.2. Market Attractiveness Index, By End User
9.2. Home care setting
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Hospitals
9.4. Others

10. By Region

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 10.1.2. Market Attractiveness Index, By Region
10.2. North America
- 10.2.1. Introduction
- 10.2.2. Key Region-Specific Dynamics
- 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.2.6.1. U.S.
  - 10.2.6.2. Canada
  - 10.2.6.3. Mexico
10.3. Europe
- 10.3.1. Introduction
- 10.3.2. Key Region-Specific Dynamics
- 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.3.6.1. Germany
  - 10.3.6.2. U.K.
  - 10.3.6.3. France
  - 10.3.6.4. Spain
  - 10.3.6.5. Italy
  - 10.3.6.6. Rest of Europe
10.4. South America
- 10.4.1. Introduction
- 10.4.2. Key Region-Specific Dynamics
- 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.4.6.1. Brazil
  - 10.4.6.2. Argentina
  - 10.4.6.3. Rest of South America
10.5. Asia-Pacific
- 10.5.1. Introduction
- 10.5.2. Key Region-Specific Dynamics
- 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 10.5.6.1. China
  - 10.5.6.2. India
  - 10.5.6.3. Japan
  - 10.5.6.4. Australia
  - 10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
- 10.6.1. Introduction
- 10.6.2. Key Region-Specific Dynamics
- 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

11. Competitive Landscape

11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis

12. Company Profiles

12.1. AbbVie
- 12.1.1. Company Overview
- 12.1.2. ProductPortfolio and Description
- 12.1.3. Financial Overview
- 12.1.4. Key Developments
12.2. Amgen
12.3. Biogen Idec
12.4. AstraZeneca
12.5. Mylan
12.6. Pfizer
12.7. Teva Pharmaceuticals
12.8. Merck & Co
12.9. Johnson &Johnson
12.10. Becton Dickinson and Company

LIST NOT EXHAUSTIVE